v3.25.4
Identifiable Intangible Assets, Net and Goodwill - Finite-lived and Indefinite-lived Intangible Assets - Footnotes (Details) - USD ($)
$ in Millions
 12 Months Ended
Nov. 13, 2025
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Finite-Lived Intangible Assets [Line Items]        
Intangible asset impairments   $ 4,940   $ 3,000
Metsera [Member]        
Finite-Lived Intangible Assets [Line Items]        
Business acquisition, cash payment $ 8,000      
Biopharma [Member]        
Finite-Lived Intangible Assets [Line Items]        
Intangible asset impairments     $ 2,900 $ 2,900
Developed Technology Rights [Member]        
Finite-Lived Intangible Assets [Line Items]        
Intangible asset impairments [1]   560    
Brand [Member]        
Finite-Lived Intangible Assets [Line Items]        
Intangible asset impairments [1]   240    
IPR&D [Member]        
Finite-Lived Intangible Assets [Line Items]        
Intangible asset impairments [1]   3,903    
IPR&D [Member] | Biopharma [Member]        
Finite-Lived Intangible Assets [Line Items]        
Intangible asset impairments   3,900    
License [Member] | Biopharma [Member]        
Finite-Lived Intangible Assets [Line Items]        
Intangible asset impairments   210    
talazoparib (Talzenna) [Member] | Developed Technology Rights [Member]        
Finite-Lived Intangible Assets [Line Items]        
Finite-lived intangible assets period increase (decrease)   590    
talazoparib (Talzenna) [Member] | IPR&D [Member]        
Finite-Lived Intangible Assets [Line Items]        
Indefinite-lived intangible assets, period increase (decrease)   (590)    
Padcev [Member] | Developed Technology Rights [Member]        
Finite-Lived Intangible Assets [Line Items]        
Finite-lived intangible assets period increase (decrease)   600    
Padcev [Member] | IPR&D [Member]        
Finite-Lived Intangible Assets [Line Items]        
Indefinite-lived intangible assets, period increase (decrease)   $ (600)    
[1] Reflects intangible assets written down to fair value in 2025. Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We started with a forecast of all the expected net cash flows for the asset and then applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the product; and assumptions about the probability of technical and regulatory success (PTRS) of ongoing clinical trials, the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.